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Abstract
Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with
high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is
usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on
data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to
the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable
future. Because the high costs of IVIg treatment also limit its ﬁrst-line use, the ﬁrst clinical guidelines on its use in derma-
tological conditions were established in 2008 and renewed in 2011.
Materials and methods The European guidelines presented here were prepared by a panel of experts nominated by
the EDF and the EADV. The guidelines were developed to update the indications for treatment currently considered as
effective and to summarize the evidence base for the use of IVIg in dermatological autoimmune diseases and TEN.
Results and conclusion The current guidelines represent consensual expert opinions and deﬁnitions on the use of
IVIg reﬂecting current published evidence and are intended to serve as a decision-making tool for the use of IVIg in der-
matological diseases.
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Introduction
Immunoglobulin preparations are obtained from the pooled
plasma of between 3000 and approximately 10 000 individual
donors. Pooling is performed to provide a species repertoire rep-
resenting all antibodies and also natural autoantibodies.
Given the large number of donors, the potential risk of trans-
mission of infectious agents such as viruses must be borne in
mind. In order to ensure a high level of quality and maximum
safety, all manufacturers of preparations derived from human
plasma must adhere to European guidelines when obtaining and
processing plasma. The Committee for Proprietary Medicinal
Products of the European Medicines Agency and the Mono-
graph in the European Pharmacopoeia govern writing and regu-
lar updating of these guidelines.
The following issues are regulated: how plasma is obtained,
the screening of donated plasma, viral safety issues, methods of
biological and pharmacological characterization and the testing
of end products for clinical efficacy. The national authorities are
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responsible for authorizing the preparations, in that they carry
out testing and define from which countries blood and plasma
may be obtained. The national authorities are also responsible
for the regular inspection of the manufacturing process and for
virological testing, as well as for the approval of any changes to
the manufacturing process.
The manufacturing pathway for immunoglobulin prepara-
tions starts with the identification of suitable donors. These
donors must be healthy and must not have any signs of infec-
tions or chronic diseases. All plasma donations must be free of
HBs antigen and anti-HCV antibodies as well as negative for
HIV-1 and HIV-2 antibodies. All plasma donations are also sub-
ject to a ‘lookback’ procedure with a holding period of at least
60 days. Any seroconversion of a donor occurring during this
time can thus be detected and all stored plasma from the donor
will be destroyed. Nucleic acid amplification technology (poly-
merase chain reaction) is used to screen the plasma from indi-
vidual donors as well as the resulting plasma pool for the
presence of HCV RNA, HBV DNA, HIV RNA, HAV RNA and
Parvovirus B19 DNA. In the event of a reactive finding, the rele-
vant plasma donations will be rejected/the plasma pool
destroyed. Besides immunoglobulin concentration steps, plasma
processing includes several independent process steps for virus
inactivation/removal. A range of both enveloped and non-envel-
oped model viruses are used to spike the test preparations in
order to quantify and validate the log reduction in virus of each
individual step in the process. In addition to the antiviral prop-
erties of the manufacturing processes, there are a number of
dedicated steps for virus inactivation/removal which vary
between manufacturers. For each batch of immunoglobulin
manufactured, a certificate is produced which provides informa-
tion on the main biological and pharmacological properties, the
degree of purity and the antibody spectrum.
Besides viral safety, the clinical efficacy of the immunoglobu-
lin preparations is also tested during this manufacturing process.
Testing of functional integrity, determination of neutralizing
antibodies and monitoring of immunomodulatory inflamma-
tory properties is carried out on the basis of established test
methods. Studies are also required in patients with primary anti-
body deficiencies. The successful treatment of patients with
chronic idiopathic thrombocytopenic purpura (ITP) is consid-
ered as evidence of the immunomodulatory activity of a prepa-
ration.
All the IVIg preparations which are commercially available at
the present time consist of intact IgG molecules with an IgG sub-
class distribution which corresponds to the normal range. The
half-life of IVIg in normal individuals is approximately 3 weeks.
The FC region of the IgG permits interaction and signal trans-
duction by FC gamma receptors on a range of immune cells. The
mechanism(s) of action of immunoglobulins is complex and has
not been elucidated completely in vivo. There has been signifi-
cant progress in understanding the multiple potential
mechanisms of action of immunoglobulin and it is likely that in
any particular condition more than one mechanism may be
operative. The roles played by FC receptors such as the inhibitory
receptor FccRIIB, the effects of Fc sialylation, as well as changes
in regulatory T cells (Tregs) and the TH17 pathway have
received recent attention.1–4 Immunoglobulins have been used
for more than 50 years in the treatment of diseases associated
with primary and secondary immune deficiency. Side-effects of
the current generation of products are generally considered to be
minimal, however, when using high-dose therapy, physicians
should be aware of uncommon serious adverse events such as
thromboembolic complications. In dermatology, IVIg is used
mainly in the treatment of autoimmune diseases and toxic epi-
dermal necrolysis (Tables 1 and 2).5 Although the list of diseases
treated is long, it is generally based on small series or isolated
case reports in uncontrolled studies. This is partly because the
number of patients with these rare conditions is too small for
large studies and it is usually difficult to compare the patients
because of the very heterogeneous clinical courses and because
of the concomitant medication used. As a result of the high costs
of treatment, use of the preparations has to be highly selective,
which makes it even more difficult to find large case series.
The aim of the current guidelines was to answer the following
questions for each clinical condition (Fig. 1):
1 Diseases for which IVIg is indicated?
2 Use of IVIg as first- or second-line treatment?
Table 1 Indications for the use of IVIg
Indications for the use of IVIg
Severe forms of dermatomyositis, inclusion body myositis, polymyositis
Toxic epidermal necrolysis
Severe forms of autoimmune blistering diseases
Severe systemic vasculitic syndromes
Severe forms of lupus erythematodes
Scleromyxedema
Less obvious indications
Atopic dermatitis
Autoimmune urticaria
Severe forms of collagen vascular diseases
Livedoid vasculopathy
Table 2 Recommended dosage regimens
Recommended dosage regimens
Dosage Total 2 g/kg bodyweight*, applied over a period of
2–5 days
Treatment interval Initially every 4 weeks/after 6 months gradually
increase to 6-week intervals†
Long-term therapy In individual cases
*3 g/kg bodyweight in toxic epidermal necrolysis.
†Only one cycle in Kawasaki0s disease and toxic epidermal necrolysis.
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3 Initial duration of treatment?
4 Interval between IVIg infusion cycles?
5 Dosing of immunoglobulin therapy?
6 Duration of treatment per IVIg cycle?
7 Methods available for assessing therapeutic efficacy?
8 Long-term treatment advisable?
Dermatomyositis
Dermatomyositis is the condition in which the highest level of
evidence exists for treatment with IVIg besides pemphigus vul-
garis.6 There are numerous individual case reports and small
case series7 as well as a double-blind, placebo-controlled cross-
over study, which demonstrate the efficacy of IVIg.8 The follow-
ing criteria were drawn up by the European Guidelines working
group:
1 Indications. All severe forms of dermatomyositis, inclusion
body myositis and polymyositis represent indications for the
use of IVIg.9 This applies also to what is referred to as idio-
pathic, paraneoplastic or juvenile forms10 respectively.
2 Timing of treatment. The data available for these diseases jus-
tifies the early use of IVIg in dermatomyositis. In patients
with a fulminant course, severe myolysis or paralysis, first-
line treatment with immunoglobulins may be justified. As a
general rule, IVIg should be used as a second-line treatment
if steroid monotherapy has failed to produce an improve-
ment after 1 month, or if reducing the steroid dose below an
acceptable level results in a flare-up of the disease, or if side-
effects prevent further steroid medication.
The use of IVIg therapy is considered to be an adjuvant treat-
ment with continuation of immunosuppressive therapy with
corticosteroids and possibly also other immunosuppressive
agents.11 IVIg monotherapy has generally been less effective.
From the immunological perspective, sufficient bone marrow
function needs to be available given the concomitant
immunosuppressive therapy. Therefore, treatment onset
should not be delayed for too long.
3 Initial duration of treatment. Initial treatment should be car-
ried out over a period of 6 months in order to determine the
efficacy of treatment with IVIg. If therapeutic efficacy has not
been achieved after 6 treatment cycles, the IVIg treatment
should be discontinued. After 18 treatment cycles, a washout
period should be attempted. It is possible to increase the
First line 
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Initiation of IVIg according to 
dosing scheme
Immunosuppressive therapy
successful?
Efficacy of therapy
Efficacy of therapy
Possible prolongation
of therapy periods
Possible prolongation
of therapy periods
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Re-initiation of 
treatment
Re-initiation of 
treatment
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End of 
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Figure 1 Decision Tree for the use of IVIg for treatment of severe autoimmune diseases in dermatology.
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interval between infusions to a maximum of 6 weeks before-
hand. In the event of recurrences, treatment can be resumed
at any time. This recommendation needs to be adapted to the
course of disease for each individual patient (some patients
need longer treatment).
4 Interval between infusions. Initially, adjuvant IVIg therapy
should be administered every 4 weeks. If a good clinical
response is achieved, the interval can be increased gradually
to a maximum of 6 weeks. Longer intervals between infu-
sions are not recommended because of the half-life of IVIg
(approximately 3 weeks).
5 IVIg dosing. The bulk of evidence with respect to the use of
IVIg in dermatological autoimmune diseases has been
obtained with a dose of 2 g/kg bodyweight per treatment
cycle. Because there is no clear evidence of efficacy with lower
doses, adherence to the aforementioned dose recommenda-
tions is advised in these serious diseases.
Although there has been one report on the successful use of
subcutaneously applied Ig in polymyositis and dermato-
myositis in seven patients, this study awaits confirmation in
larger patient cohorts.12 Therefore, s.c. Ig cannot generally be
recommended in dermatomyositis.
6 Period of IVIg administration. Administration of the
immunoglobulin should be spread over 2-5 consecutive days.
Tolerability is generally better with greater dose fractionation.
In patients with cardiac or renal impairment, immunoglobu-
lin preparations should be administered over a longer period
of time. If the treatment is well tolerated at the beginning, it
can generally also be carried out on an outpatient basis.
7 Evaluation of therapeutic efficacy. The clinical picture is the
most important parameter for evaluating the efficacy of treat-
ment in dermatomyositis, with evaluation of muscle strength
playing the most important role. Autoantibody titres, on the
other hand, do not reflect the response to treatment. In gen-
eral, creatine kinase and muscle aldolase levels also return
rapidly to normal under immunosuppressive therapy. This
prohibits their use as indicators of efficacy. MRI or ultra-
sonography of the proximal muscle groups is important for
the initial diagnosis as is specific muscle biopsy, but are
unsuitable for close monitoring. The criteria for evaluating
the clinical response is therefore normalization of muscle
strength with gradual tapering of the steroid dose, fading of
erythema and gradual resolution of other parameters such as
Gottron’s papules while on IVIg therapy. It is our experience
that a response can be detected from the second treatment
cycle on, mainly by the patient (especially on the basis of the
improvement in muscle strength) but also by the treating
physician. Nevertheless, tapering the concomitant medication
too rapidly should be avoided. Between three and four treat-
ment cycles are often required before a significant improve-
ment in symptoms is seen and in severely affected patients,
extension of treatment intervals needs to be done with care.
8 Long-term IVIg therapy. In rare cases, long-term therapy may
be necessary in patients with severe dermatomyositis and a
prolonged course, although therapy-cessation periods should
be attempted to allow the effects of the IVIg therapy on the
course of the disease to be assessed.
Autoimmune blistering diseases
The autoimmune blistering diseases are autoantibody-mediated
disorders, the autoantigens of which are largely known and have
been molecularly characterized. Autoimmune blistering diseases
are generally treated by dermatologists only and are therefore of
great importance for our speciality. The following recommenda-
tions were drawn up for the use of IVIg in these diseases:
1 Indication. All severe forms of autoimmune blistering diseases,
which are refractory to therapy or relapsing after therapy13
represent an indication for the use of IVIg. In fact, a random-
ized controlled trial14 as well as an extensive literature review15
have confirmed these evidence levels. The experiences are par-
ticularly good in pemphigus vulgaris, pemphigus foliaceus,
mucous membrane pemphigoid16 and epidermolysis bullosa
acquisita. However, the use of IVIg may also be indicated in
severe forms of bullous pemphigoid, linear IgA disease, IgA
pemphigus or paraneoplastic pemphigus.
2 Timing of treatment. On the basis of the scientific evidence
available, the use of IVIg cannot be recommended as a
first-line treatment. However, contraindications to standard
immunosuppressive therapy (e.g. aseptic bone necrosis,
poorly controlled diabetes or advanced osteoporosis and cat-
aracts) may justify the use of IVIg as a first-line treatment in
isolated cases. Consequently, immunoglobulins should pri-
marily be used as a second-line treatment following sufficient
combination therapy with steroids (e.g. prednisolone 1–
2 mg/kg bodyweight per day) and another immunosuppres-
sive agent, e.g. azathioprine or mycophenolate mofetil.17,18
Here again, IVIg is an adjuvant therapy, which must be
administered while continuing the conventional immuno-
suppressive therapy. IVIg may also be considered in patients
treated with rituximab in whom sufficient disease control
was not attained. This also means that immunoglobulin use
should not be delayed for too long because adjuvant treat-
ment is useful only with concomitant immunosuppressive
therapy and this requires adequate bone marrow function.
Monotherapy with immunoglobulin is generally not recom-
mended.
3 Initial duration of treatment. Treatment should be adminis-
tered initially for a period of between 3 and 6 months in
order to assess the efficacy of the IVIg in each individual case.
Some patients do not show a definitive sustained response
until they have undergone up to six cycles of treatment. If a
therapeutic response cannot be documented after six cycles
of therapy, IVIg treatment should be discontinued. This rec-
ommendation needs to be adapted to the course of disease
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for each individual patient (some patients may need longer
treatment).
4 Interval between infusions. Adjuvant therapy with IVIg should
be administered every 4 weeks initially. If the clinical
response is good, the interval between infusions can be
increased gradually to a maximum of 6 weeks. Longer inter-
vals are not recommended because of the half-life of IVIg.
5 Dosing. As already mentioned above, most studies have used
a total dose of 2 g/kg bodyweight by intravenous infusion.
Because only insufficient data are available at present for
higher or lower doses, this dosage should be considered as
the standard recommendation at present.
6 Period of treatment. As already mentioned above, treatment
should be administered over a period of 2–5 days, with frac-
tionated administration of the IVIg therapy contributing to
better tolerability.
7 Evaluation of treatment efficacy. Both clinical and serological
parameters are used for evaluating the efficacy of treatment
in most blistering autoimmune diseases. The criteria for eval-
uating the clinical picture are therefore cessation of blistering
and healing of existing lesions under adjuvant IVIg therapy.
At the same time, a moderate reduction in concomitant
immunosuppressive treatment should be possible without
recurrence. Serological parameters such as IgG autoantibody
titres measured by ELISA or indirect immunofluorescence
microscopy may provide an additional parameter to evaluate
the therapeutic efficacy of IVIg.
8 Long-term therapy. Long-term therapy with IVIg is recom-
mended only in rare cases especially when mucous mem-
branes are severely affected. An exception to this are patients
in whom disease recurrence occurs after withdrawal of IVIg
therapy and no other treatment options exist, and if this is
the case, combination therapy with rituximab may be consid-
ered. Regular washout periods should be attempted.
Vasculitic syndromes
Vasculitic syndromes are systemic inflammatory conditions
which affect the blood vessels of one or more organ system. A
distinction is made between primary and secondary systemic
vasculitic syndromes. Because the skin is often involved as an
indicator organ and the conditions often prove highly refractory
to treatment, immunoglobulin is often considered as a therapeu-
tic alternative. The following recommendations can be made on
the basis of our current state of knowledge:
1 Indication. Kawasaki’s disease is the only disease in this cate-
gory for which IVIg is the first-line treatment. In all other
cases, primary treatment generally consists of high-dose cor-
ticosteroids together with additional immunosuppressive
agents such as cyclophosphamide or others. The use of these
aggressive immunosuppressive regimens is often associated
with severe side-effects, and recurrences occur on withdrawal
or dose reduction. In patients who do not respond to
standard therapy or those with a particularly fulminant pro-
gressive disease, IVIg therapy may be considered as an early
treatment option. All forms of severe vasculitis19 can repre-
sent potential indications for IVIg.20 Particularly, positive
results have been achieved in primary vasculitis, e.g. chronic
polyangiitis (Wegener’s granulomatosis), polyarteritis
nodosa, IgA-associated vasculitis, Churg–Strauss disease,21
microscopic polyangiitis and in secondary autoimmune vas-
culitis. Good results have also been achieved in patients with
anti-phospholipid antibody syndrome.22
2 Timing of treatment. IVIg is only approved for Kawasaki0s
syndrome as a first-line treatment. As already mentioned
above, treatment in all other indications is considered as
adjuvant therapy only after failure of immunosuppressive
therapy or in the presence of contraindications. The early use
of IVIg may, however, prevent massive tissue destruction and
thus reduce the extent of damage in conditions such as haem-
orrhagic necrotizing vasculitis of the skin or in Wegener’s
granulomatosis.
3 Initial duration of treatment. As with the aforementioned
indications, a treatment period of 3–6 months is useful ini-
tially in order to obtain a clear idea of the response to treat-
ment.
4 Interval between infusion. As described above, treatment
should be administered at 4-week intervals initially. If the
clinical response is good, the intervals between infusions can
be extended gradually to a maximum of 6 weeks. A clear ben-
efit of longer treatment intervals has not been documented.
5 Dosing. The recommended dose for the treatment of
Kawasaki syndrome in children is again 1.6–2 g/kg body-
weight per treatment cycle (as bolus infusion or divided
into single infusions given over 2–5 days) in addition to
the recommended administration of acetylsalicylic acid
with an initial dose of 50 mg/kg bodyweight per day. On
the basis of this, all case series of patients with systemic
vasculitic syndromes have so far been treated with a total
dose of 2 g/kg bodyweight.
6 Duration of treatment. Treatment should be administered
over a period of 2–5 days, with a longer duration of treat-
ment being associated with fewer side-effects. In the case of
systemic vasculitis with renal involvement in particular, the
infusion rate should be reduced or possibly a reduced dose
should be used (e.g. a total of 1 g/kg bodyweight).
7 Evaluation of treatment efficacy. The clinical response should
be the main criterion used for evaluating therapeutic efficacy.
Because organ involvement is rather heterogeneous, only
general recommendations can be expressed here. The pattern
of c-reactive protein (CRP) and organ-specific laboratory
tests, can be used as indicators of response. As an example, in
Wegener’s granulomatosis, the c-ANCA titre and level of the
proteinase 3 (PR3) ELISA can be used as additional indica-
tors.
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8 Long-term therapy. Long-term therapy with IVIg is recom-
mended only in exceptional cases.
Lupus erythematosus, and other collagen vascular
diseases
Almost all autoimmune connective tissue diseases have already
been treated experimentally with IVIg in small series. The best
data exist for systemic lupus erythematosus. The following rec-
ommendations are proposed:
1 Indication. All severe cases of lupus erythematosus can repre-
sent an indication for attempted treatment with IVIg if no
other treatment options are available. Its use in systemic lupus
erythematosus, especially in lupus nephritis,23 is considered
effective. Less clear are the data in patients with scleroderma,
in which no clear recommendation can be expressed.24 Care
should be taken in the setting of connective tissue disease as
the infusion of IVIg in patients with high titre rheumatoid
factor (RF) has been associated with renal damage.
2 Timing of treatment. The use of IVIg is generally not a first-
line treatment option. Previous combination treatment with
steroids and another immunosuppressive associated with a
poor response or severe complications is considered an indi-
cation for the use of IVIg. Again, however, the use of IVIg
should not be delayed for too long in conditions such as
lupus nephritis to avoid tissue damage. Here too, treatment
should be given in combination with adequate immunosup-
pressive therapy.
3 Initial duration of treatment. As with the aforementioned
conditions, application of IVIg is initially recommended over
a period of 6 months. If there has been no response to treat-
ment after this time, treatment should be discontinued.
4 Interval between infusions. The initial interval between infu-
sions should again be 4 weeks. The interval between the indi-
vidual bolus infusions can then be increased gradually to
6 weeks. Any additional increase in the interval is not useful
because of the half-life of immunoglobulin.
5 Dosing. Again, the only experience available in the conditions
listed above is with the standard dose of 2 g/kg bodyweight.
This should be adopted as the standard recommendation.
6 Treatment period. Treatment should be administered over a
period of 2–5 days. In the case of severe organ involvement
such as kidney or heart involvement in particular, the treat-
ment period should be increased to 5 days.
7 Evaluation of treatment efficacy. The focus is again on the
clinical evaluation of treatment efficacy. Because this is a very
heterogeneous group of diseases, it is only possible to express
the general recommendation that improvement in primary
organ involvement (e.g. protein excretion in the urine)
should be used as an indicator of response. In isolated cases,
the pattern of disease-specific autoantibodies such as double-
strand DNA antibodies can be used as an indicator of
response in systemic lupus erythematosus.
8 Long-term therapy. Long-term therapy can be recommended
only in exceptional cases.
Scleromyxedema
Scleromyxedema is a severe multi-organ condition characterized
by fibroblast proliferation and mucin deposition in skin and
internal organs associated with monoclonal gammopathy in the
majority of cases. Thickening and fibrosis of skin often cause a
debilitating situation and internal organ involvement can put
the patient’s life at risk.25,26 Scleromyxedema is refractory to
most classical immunosuppressive therapies, but responds
quickly to treatment with IVIg, as documented in many case
reports and in small case series.27,28 The body of evidence on
efficient therapy of scleromyxedema with IVIg has substantially
grown since the first report of efficacy in 200026,29 leading to the
addition of this disease to the current guidelines. The following
recommendations are proposed:
1 Indication. All severe cases of scleromyxedema represent
an indication for a treatment attempt with IVIg as treat-
ment with other immunosuppressive agents is often not
effective. Its use in scleromyxedema is considered effec-
tive.26,30,31
2 Timing of treatment. IVIg should be considered treatment of
choice in refractory cases of scleromyxedema with either fast
deterioration of skin symptoms, the dermato-neuro syn-
drome or life-threatening involvement of internal organs. In
milder cases, initial treatment with immunosuppressive regi-
mens should be undertaken. Failure to respond to such treat-
ment or contraindications to such treatments justify
initiation of treatment with IVIg. In scleromyxedema no
additional treatments are needed besides IVIg.
3 Initial duration of treatment. As with the other conditions,
the use of IVIg is initially recommended over a period of
6 months. If there has been no response to treatment after
this time, treatment should be discontinued.
4 Interval between infusions. The initial interval between infu-
sions should be 4 weeks. The interval between the individual
bolus infusions can then be increased gradually to 6 weeks.
Any additional increase in the interval is not useful because
of the half-life of immunoglobulin.
5 Dosing. Most experience in scleromyxedema exists with the
standard dose of 2 g/kg bodyweight. This should be adopted
as the standard recommendation.
6 Treatment period. Treatment should be administered over a
period of 2–5 days. In the case of severe organ involvement
such as kidney or heart involvement in particular, the treat-
ment period should be increased to 5 days.
7 Evaluation of treatment efficacy. The focus lies on the clinical
evaluation of treatment efficacy. As skin involvement is pre-
sent in nearly all cases and responds very well to treatment
with IVIg, it should be used as an indicator of response. In
isolated cases, clinical response to CNS or internal organ
© 2016 European Academy of Dermatology and VenereologyJEADV 2016
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involvement can be used as additional indicator of response
in scleromyxedema.
8 Long-term therapy. It has been documented in several cases
that after discontinuation of IVIg there are relapses.26,32 If a
relapse is severe and life-threatening, long-term therapy can
be recommended in exceptional cases.
Toxic epidermal necrolysis
Toxic epidermal necrolysis represents a life-threatening side-
effect of drugs.33 The condition is associated with Fas (CD95)
and granulysin-mediated apoptosis, as well as annexin A1-
mediated necroptosis of epidermal keratinocytes.34 Therefore, it
is assumed that antibodies interfering with these apoptotic path-
ways (and contained in IVIg preparations) might be beneficial in
this disease.35 Because of its life-threatening and fulminant pro-
gressive course with detachment of large areas of the epidermis
in severe cases, these patients are at acute risk of infection and
must receive intensive care. The condition is nevertheless lethal
in up to 40% of cases. The following recommendations have
been drawn up for the use of IVIg:
1 Indication. In certain studies, the early administration of high
doses of IVIg in toxic epidermal necrolysis was suggested to
be potentially life-saving. A systematic review and meta-ana-
lysis of observational controlled studies published before 31
July 2011 indicated that high-dose IVIg (≥2 g/kg) was associ-
ated with significantly lower mortality than low-dose IVIg
(<2 g/kg, P = 0.022).36 The pooled odds ratio for mortality
in patients treated with IVIg (all doses confounded) vs. sup-
portive care was, however, not significantly reduced at 0.63
(P = 0.27). A subsequent meta-analysis of 13 published stud-
ies between 1996 and 2011 in which severity of disease had
been determined with SCORTEN, revealed again a non-sig-
nificant reduction in standardized mortality rate of 0.322
(P = 0.155) in patients treated with IVIg (all doses con-
founded), but a strong and significant inverse correlation
between IVIg dosage and standardized mortality rate
(P = 0.009), showing that IVIg at dosages of ≥2 g/kg signifi-
cantly decreased mortality compared to that expected in
patients with SJS or TEN.37 Although the mechanism of
action remains unclear, the early administration of high-dose
immunoglobulin may be considered in confirmed cases of
toxic epidermal necrolysis in the absence of an alternative
evidence-based therapeutic alternative given that the poten-
tial benefits of high-dose IVIg outweigh the risks of the medi-
cation and the disease’s natural course.
2 Timing of treatment. Unlike in the aforementioned condi-
tions, IVIg should be administered as soon as possible after
confirmation of the diagnosis. IVIg treatment can then be
administered as monotherapy in addition to supportive mea-
sures including intensive care. The concomitant administra-
tion of corticosteroids or immunosuppressive agents is
controversial.
3 Initial duration of treatment. Only one cycle of treatment is
usually required in this condition, administered over a period
of 3–5 days.
4 Dosing. The dose recommendation in toxic epidermal necrol-
ysis differs from that in autoimmune diseases. A total dose of
at least 3 g/kg bodyweight is generally recommended. Frac-
tionated administration (over 3–5 days) is required, particu-
larly in the case of risk factors including renal impairment,
pre-existing cardiovascular disease and diabetes in these
patients.
5 Evaluation of treatment efficacy. The cessation of ongoing epi-
dermal detachment and the onset of re-epithelialization are
good clinical parameters for evaluating treatment efficacy,
but survival remains the most valid clinical outcome mea-
sure. The contribution of IVIg to the healing process is diffi-
cult to assess.
6 Long-term therapy. Not applicable.
Other possible treatment indications
IVIg has been described as an effective treatment method in
numerous clinical conditions in dermatology. Some of the more
frequent entities will be mentioned here, although a conclusive
assessment is not possible at present (Table 1).
Atopic dermatitis According to the literature available and iso-
lated case reports, the use of IVIg should definitely be considered
in the most severe forms of atopic eczema. According to reports
in the literature, healing can in some cases be significantly accel-
erated in cases which are refractory to conventional treat-
ment.38,39
Autoimmune urticaria The use of immunoglobulin can also be
considered as a last resort in severe cases of autoimmunologi-
cally mediated urticaria. Only single case reports and smaller
case series are available at present in this indication, and these
describe the successful use of immunoglobulin at the aforemen-
tioned standard dose.39 A conclusive assessment of these reports
is not possible at the present time and newer therapies including
anti-IgE monoclonal antibodies may play a greater role in ther-
apy-resistant urticaria in the future.
Pyoderma gangrenosum The use of IVIg can be considered as
an option in severe refractory cases of pyoderma gangrenosum.
As only small case series are available at present time, no general
consensus statement is possible at present time.
Livedoid vasculopathy Numerous case studies have reported
on the successful use of IVIg in therapy-resistant livedoid
vasculopathy.40,41 Although no general recommendation can
be given at this point, the amount of evidence for a positive
effect of IVIg is increasing, justifying their use in desperate
cases.
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Summary
The treatment recommendations presented for the use of IVIg in
dermatology highlight the importance of IVIg therapy in numer-
ous defined dermatological autoimmune diseases and in toxic
epidermal necrolysis. The value of IVIg therapy in diseases which
are otherwise refractory to treatment is undisputed. Clear treat-
ment recommendations can therefore be given for the diseases
described above (Tables 1 and 2). Because the exact mechanisms
of action of IVIg in vivo are still unclear in these conditions, fur-
ther efforts should be made to launch randomized controlled tri-
als despite the rarity of some of the disorders described. The
current guideline recommendations are intended to create a
basis for future randomized controlled trials. The implementa-
tion of this EU guideline in general practice means that the use
of IVIg in dermatology will be optimized throughout Europe.
Methodology/Additional information
The European guidelines presented here were prepared by a
panel of experts nominated by the EDF and the EADV in order
to present the indications for treatment currently considered as
effective and to summarize the evidence base for the use of IVIg.
These guidelines are intended to support informed therapeu-
tic decision-making on the use of IVIg for dermatologists.
The current guidelines represent consensual expert opinions
and definitions on the use of IVIg reflecting current published
evidence. The guidelines were prepared based on two rounds of
evaluation of the previous guidelines (2011) with an individual
update by each representative expert on the panel followed by a
separate meeting of all panel members with discussion on the
identified topics. The email-based evaluation period and the fol-
lowing expert panel meeting with discussion were coordinated
and moderated by Professor Dr. med. A. Enk. An informal con-
sensus was reached during the panel discussions, a structured
formal consensus procedure was not applied.
The guidelines project did not receive financial support. The
expert group did not receive financial incentives or reimburse-
ment for the participation in the guidelines development. The
summary of evidence was done independently from industrial
interest.
A declaration of potential conflicts of interest (COI) adapted
from the International Committee of Medical Journal Editors
was required for the participation in the guidelines development.
COIs were discussed. The expert group did not see any substan-
tial conflicts of interest and there were no further comments or
remarks. COI of each person involved in the guidelines develop-
ment are presented in the appendix.
External reviewing was done according to EDF SOP for guide-
lines development over a period of 4 weeks, including the mem-
bers of the EDF guidelines commission, the EADV Board and
the Union Europeenne des Medecins Specialistes. During the
review period, the draft was piloted within the departments of
the participating experts. Comments and necessary changes
coming from the external review were being discussed among
the authors. European guidelines are subject to national or
regional adaptation with consideration of local circumstances
(regulatory approval and availability of treatments, health care
provider and insurance systems). Thus, the national medical
societies associated to the EDF will be responsible for the adap-
tion and implementation of the guidelines on a national level.
Due to the increasing amount of publications, guidelines need
to be continually updated to reflect the recent state of evidence.
After 31 December 31 2019, these guidelines will expire. Should
important changes occur in the meantime, such as new available
interventions, new important evidence or withdrawal of drug
licensing, the information contained in the guidelines will be
updated earlier. In these cases, an update issue of the guidelines
is needed earlier. The EDF in cooperation with the current
guidelines coordinator (Enk) will be responsible to initiate an
update.
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